Back

Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy of acute coronary syndromes in clinical practice Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Beta-blockers after STEMI: prognostic impact and predictors of adherence, results from the real-world FAST-STEMI registry
Doctor E. Ravetti (Orbassano, IT)
Abstract Slides Video
Presentation thumbnail
Changes of hospital-level variation in use of optimal medical treatment for long-term follow-up from a multi-level methodological approach
Doctor H. Kwak (Daegu, KR)
Abstract Slides
Presentation thumbnail
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
Professor R. Marcucci (Florence, IT)
Abstract Slides Video
Presentation thumbnail
One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk
Doctor C. Pivato (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Ticagrelor versus Clopidogrel in diabetes patients afflicted with acute coronary syndrome stratified by renal function
Doctor T. Wang (Taipei, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy of acute coronary syndromes in clinical practice

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Exploring residual cardiovascular risk beyond LDL cholesterol in patients with acute destabilisation of known significant atherosclerosis
thumbnail
Congress Presentation
Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome
thumbnail
Congress Presentation
Risk of recurrent ischaemic events in ACS patients with baseline LDL-C below guideline-recommended thresholds: insights from the prospective SPUM-ACS study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources